Actinium Pharmaceuticals (ATNM)
:ATNM
Want to see ATNM full AI Analyst Report?
Top Page
Actinium Pharmaceuticals
(ATNM)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.00
▼(-23.08% Downside)
Action:ReiteratedDate:04/21/26
The score is held down primarily by weak financial performance (minimal revenue, ongoing large losses, and persistent cash burn with reduced equity cushion). Technicals are supportive in the near term (price above major moving averages and positive MACD) but are tempered by overbought momentum readings. Valuation is constrained by negative earnings and no provided dividend yield.
Positive Factors
Low Absolute Leverage
Modest absolute debt provides durable financial flexibility for a clinical-stage biotech. Lower leverage reduces near-term bankruptcy risk and preserves capacity to raise capital or secure partnership arrangements without immediate heavy interest burdens, aiding program funding options.
Negative Factors
Minimal and Declining Revenue
Revenue has collapsed to a negligible base, removing any near-term operating cushion and increasing dependency on external capital. Sustained minimal revenue undermines the firm's ability to internally fund trials or scale operations, making strategic plans contingent on financing or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Absolute Leverage
Modest absolute debt provides durable financial flexibility for a clinical-stage biotech. Lower leverage reduces near-term bankruptcy risk and preserves capacity to raise capital or secure partnership arrangements without immediate heavy interest burdens, aiding program funding options.
Read all positive factors
Actinium Pharmaceuticals (ATNM) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$38.90M
Dividend YieldN/A
Average Volume (3M)208.30K
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue GrowthN/A
EPS Growth14.71%
CountryUS
Employees31
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.08
Shares Outstanding31,374,994
10 Day Avg. Volume380,172
30 Day Avg. Volume208,296
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.42
Price to Sales (P/S)471.40
P/FCF Ratio-1.72
Enterprise Value/Market Cap-0.19
Enterprise Value/Revenue-82.21
Enterprise Value/Gross Profit-82.21
Enterprise Value/Ebitda0.22
Forecast
1Y Price Target
$6.00Price Target Upside361.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.89
Revenue Forecast (FY)N/A
Actinium Pharmaceuticals Business Overview & Revenue Model
Company Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product...
How the Company Makes Money
null...
Actinium Pharmaceuticals Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Mar 2023 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 90.00K | 0.00 | 81.00K | 1.03M | 1.14M |
| Gross Profit | 90.00K | -811.00K | 81.00K | 1.03M | 620.00K |
| EBITDA | -35.43M | -37.43M | -51.13M | -33.41M | -24.25M |
| Net Income | -33.89M | -38.24M | -48.82M | -33.02M | -24.77M |
Balance Sheet | |||||
| Total Assets | 51.77M | 76.90M | 81.44M | 114.19M | 80.39M |
| Cash, Cash Equivalents and Short-Term Investments | 48.00M | 72.90M | 76.68M | 108.91M | 77.83M |
| Total Debt | 1.69M | 1.57M | 2.11M | 2.58M | 310.00K |
| Total Liabilities | 43.94M | 44.14M | 45.07M | 47.71M | 6.84M |
| Stockholders Equity | 7.83M | 32.76M | 36.38M | 66.48M | 73.55M |
Cash Flow | |||||
| Free Cash Flow | -24.68M | -33.08M | -47.49M | 8.28M | -21.00M |
| Operating Cash Flow | -24.58M | -33.07M | -47.34M | 8.64M | -20.87M |
| Investing Cash Flow | -104.00K | -11.00K | -153.00K | -366.00K | -133.00K |
| Financing Cash Flow | -217.00K | 29.32M | 14.87M | 23.11M | 35.22M |
Actinium Pharmaceuticals Technical Analysis
Positive
1.30
Price Trends
1.12
Positive
1.26
Positive
1.41
Negative
Market Momentum
0.03
Negative
65.56
Neutral
87.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATNM, the sentiment is Positive. The current price of 1.3 is above the 20-day moving average (MA) of 1.11, above the 50-day MA of 1.12, and below the 200-day MA of 1.41, indicating a neutral trend. The MACD of 0.03 indicates Negative momentum. The RSI at 65.56 is Neutral, neither overbought nor oversold. The STOCH value of 87.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATNM.
Actinium Pharmaceuticals Risk Analysis
Actinium Pharmaceuticals disclosed 59 risk factors in its most recent earnings report. Actinium Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Actinium Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $180.73M | -1.64 | -81.77% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $38.90M | -1.79 | -204.37% | ― | ― | 14.71% | |
48 Neutral | $205.18M | -15.62 | -111.37% | ― | ― | 80.61% | |
46 Neutral | $81.47M | -5.85 | -237.54% | ― | ― | 35.75% |
* Healthcare Sector Average
ATNM
Actinium Pharmaceuticals
1.24
-0.19
-13.29%
IFRX
InflaRx
2.50
0.92
58.23%
GANX
Gain Therapeutics
1.91
-0.11
-5.45%
UNCY
Unicycive Therapeutics
8.13
1.91
30.71%
ANL
Adlai Nortye Ltd. Sponsored ADR
14.27
12.43
675.54%
JUNS
Jupiter Neurosciences, Inc.
0.36
-0.26
-41.45%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.